J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

GSK’s share price has been pressured recently from several negative events, but this may leave a bargain to be had. I've ...

The GSK (LSE: GSK) share price seems to have gained some momentum over the past six months, rising over 15%. Half of this growth has come in 2024 alone. Even after this share price rise ...

The user of the website is referred to as "you" and "your". By posting on our share chat boards you are agreeing to the following: If you are going to post non-English, please also post an English ...

What was Glaxosmithkline Pharmaceuticals Ltd share price previously? Glaxosmithkline Pharmaceuticals Ltd share price was down by 0.00% from the previous closing price of ₹2,107.85. Who are peers ...

(Alliance News) - Pharmaceutical firm GSK PLC and the University of Oxford are creating a new cancer vaccine to prevent the disease from developing. The partnership intends to create a vaccine or ...

GlaxoSmithKline (GSK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from ...

(Alliance News) - GSK PLC on Tuesday said applications for its treatment for a type of asthma and chronic rhinosinusitis with nasal polyps, or CRSwNP, have been accepted for review in China, Japan and ...

The company said under a collaboration with the university it would invest £50m over three years to find out whether cancers could be prevented from developing with jabs.

GSK’s share price has been pressured recently from several negative events, but this may leave a bargain to be had. I’ve investigated whether this is the case. When investing, your capital is ...

By posting on our share chat boards you are agreeing to the ... such as trade deals or improved market access, GSK could enhance its foothold in the region. However, these benefits hinge on ...